Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical Developments International’s (MVP) Penthrox drug has been granted market authorisation in Thailand
  • This authorisation means that Penthrox can now be used for pain relief in adult patients with moderate to severe pain
  • Penthrox is a rapid onset painkiller that is inhaled by conscious patients who are in pain or are about to be operated on
  • MVP is now planning to resubmit its investigational new drug application for Penthrox in the U.S.
  • Company shares are up 2.41 per cent and are currently trading for $7.64 each

Medical Developments International’s (MVP) Penthrox drug has been granted market authorisation in Thailand.

The authorisation was issued by the Thailand Food and Drug Administration, so Penthrox can now be used for emergency relief in conscious adult patients with moderate to severe pain.

“This is an important approval, as Thailand is a key market for Penthrox throughout the Asian Region,” Chairman David Williams stated.

“It is the first approval we have obtained with our partners Daiichi Sankyo, who are also our partners in China and Vietnam,” he said.

“We hope this approval is a catalyst for a number of other country approvals in Asia,” he added.

Penthrox is a rapid onset, non-narcotic analgesic (painkiller) that is inhaled by conscious patients, under the supervision of trained personnel, who are in pain or are about to be operated on.

Since the patients administer it themselves, they can control the amount of painkiller they receive.

In the company’s half year report, it announced that sales for Penthrox grew 18 per cent in Australia, 35 per cent in the European Union, 42 per cent in the U.K. and Ireland, and 24 per cent in New Zealand.

MVP says its ambition is to complete the roll out of Penthrox into Mexico, Iran, South Korea, and Jordan, and resubmit its IND (investigational new drug) application for Penthrox in the U.S.

Company shares are up 2.41 per cent and are trading for $7.64 each at 1:08 pm AEST.

MVP by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug